Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Black tea is a beverage and dietary supplement derived from the fully oxidized leaves of the Camellia sinensis plant. It contains caffeine, polyphenols (notably theaflavins and thearubigins), catechins, tannins, amino acids (such as L-theanine), vitamins (A, C, K), phenolic acids (caffeic acid, gallic acid), and other bioactive compounds[2][4]. Black tea acts primarily as a central nervous system stimulant due to its caffeine content. Its polyphenols have antioxidant properties and may contribute to cardiovascular health by promoting vasodilation through activation of potassium channels in blood vessels[7]. Black tea has been studied for potential benefits in alertness/energy enhancement, heart health, cholesterol reduction, metabolic support, gut health modulation via antioxidants/polyphenols/catechins/tannins/flavonoids[2][4], and possible antihypertensive effects via KCNQ5 potassium channel activation[7]. It is not an approved pharmaceutical drug but is widely consumed as a beverage or supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on black tea.